Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate

Cancer Letters

Volumn 258, Issue 2, 2007, Pages 165-170

  Reni, Michele ^a   Mazza, Elena ^a   Foppoli, Marco ^a   Ferreri, Andrés J M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

High dose methotrexate; Primary central nervous system lymphomas; Salvage treatment; Temozolomide

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; IBRITUMOMAB TIUXETAN; METHOTREXATE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN;

B CELL LYMPHOMA; BLOOD BRAIN BARRIER; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; INTRAOCULAR TUMOR; LEUKOENCEPHALOPATHY; LEUKOPENIA; MONOTHERAPY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; REMISSION; SALVAGE THERAPY; SHORT SURVEY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 36048963863     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.009     Document Type: Review

References (24)

1. Reni M., Ferreri A.J.M., Garancini M.P., and Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann. Oncol. 8 (1997) 227-234
2. Ferreri A.J.M., Reni M., and Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann. Oncol. 11 (2000) 927-937
3. Ferreri A.J.M., Reni M., Pasini F., Calderoni A., Tirelli U., Pivnik A., Aondio G.M., Ferrarese F., Gomez H., Ponzoni M., Borisch B., Berger F., Chassagne C., Iuzzolino P., Carbone A., Weis J., Pedrinis E., Motta T., Jouvet A., Barbui T., Cavalli F., Blay J.Y., and for the International Extranodal Lymphoma Study Group. A multicenter study of treatment of primary CNS lymphoma. Neurology 58 (2002) 1513-1520
4. A.J. Ferreri, L.E. Abrey, J.Y. Blay, B. Borisch, J. Hochman, E.A. Neuwelt, J. Yahalom, E. Zucca, F. Cavalli, J. Armitage, T. Batchelor, Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15 2002, J. Clin. Oncol. 21 (2003) 2407-2414.
5. Reni M., and Ferreri A.J. Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas?. J. Clin. Oncol. 22 (2004) 1165-1167
6. Reni M., Ferreri A.J.M., Guha-Thakurta N., Blay J.-Y., Dell'Oro S., Biron P., and Hochberg F.H. The clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 419-425
7. Reni M., Ferreri A.J.M., and Villa E. Second-line treatment for primary central nervous system lymphoma. Br. J. Cancer 79 (1999) 530-534
8. Jahnke K., Thiel E., Martus P., et al. Relapse of PCNSL: clinical features, outcome and prognostic factors. J. Neurooncol. 80 (2006) 159-165
9. Reni M., Mason W., Zaja F., Perry J., Franceshi E., Bernardi D., Dell'Oro S., Stelitano C., Candela M., Abbadessa A., Pace A., Bordonaro R., Latte G., Villa E., and Ferreri A.J.M. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur. J. Cancer 40 (2004) 1682-1688
10. Reni M., Zaja F., Mason W., Perry J., Mazza E., Spina M., Bordonaro R., Ilariucci F., Faedi M., Corazzelli G., Manno P., Franceschi E., Pace A., Candela M., Abbadessa A., Stelitano C., Latte G., and Ferreri A.J. Temozolomide as salvage treatment in primary brain lymphomas. Br. J. Cancer 96 (2007) 864-867
11. Fischer L., Thiel E., Klasen H.A., Birkmann J., Jahnke K., Martus P., and Korfel A. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol. 17 7 (2006) 1141-1145
12. Plotkin S.R., Betensky R.H., Hochberg F.H., et al. Treatment of relapsed PCNSL with high-dose methotrexate. Clin. Cancer Res. 10 (2004) 5643-5646
13. Tyson R.M., Siegal T., Doolittle N.D., Lacy C., Kraemer D.F., and Neutwelt E.A. Current status and future of relapsed primary central nervous system lymphoma (PCNSL). Leukemia Lymphoma 44 (2003) 627-633
14. Arellano-Rodrigo E., Lopez-Guillermo A., Bessell E.M., Nomdedeu B., Montserrat E., and Graus F. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur. J. Haematol. 70 (2003) 219-224
15. Enting R.H., Demopoulos A., DeAngelis L.M., and Abrey L. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63 (2004) 901-903
16. P. Kiewe, A. Korfel, S. Maza, et al., Penetration of Yttrium-90-labeled ibritumomab tiuxetan (Zevalin™) into primary CNS lymphoma, ASH Annual Meeting Abstracts, 2006, 108, Abstract 2724.
17. Nguyen P.L., Chakravarti A., Finkelstein D.M., Hochberg F., Batchelor T.T., and Loeffler J.S. Results of whole brain radiation as salvage of MTX failure for immunocompetent patients with primary central nervous system lymphoma. J. Clin. Oncol. 23 (2005) 1507-1513
18. Herrlinger U., Kuker W., Uhi M., et al. NOA-03 trial of high-dose MTX in primary central nervous system lymphoma: final report. Ann. Neurol. 57 (2005) 843-847
19. Glass J., Gruber M.L., Cher L., and Hochberg F.H. Preirradiation MTX chemotherapy of primary central nervous system lymphoma: long term outcome. J. Neurosurg. 81 (1994) 188-195
20. O'Brien P., Roos D., Pratt G., et al. Phase II multicentre study of brief single-agent MTX followed by irradiation in primary CNS lymphoma. J. Clin. Oncol. 18 (2000) 519-526
21. O'Brien P., Roos D., Pratt G., et al. Combined modality therapy for primary CNS lymphoma: long-term data from a phase II multicentre study (Trans-Tasman Radiation Oncology Group). Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 408-413
22. Soussain C., Suzan F., Hoang-Xuan K., et al. Results of intensive chemotherapy followed by hematopietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J. Clin. Oncol. 19 (2001) 742-749
23. C. Soussain, K. Hoang-Xuan, L. Taillander, et al., Intensive chemotherapy followed by hematopoietic stem cell rescue for refractory or recurrent PCNSL or intra ocular lymphoma. Results of a multicentric phase II study, ASH Annual Meeting Abstracts, Part 1, vol. 108, issue 11, 2006 (November 16).
24. Rubenstein J.L., Fridlyand J., Abrey L., et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J. Clin. Oncol. 25 (2007) 1350-1356